Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Assets (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Current Assets data on record, last reported at $2.3 billion in Q4 2025.

  • For Q4 2025, Current Assets rose 66.52% year-over-year to $2.3 billion; the TTM value through Dec 2025 reached $2.3 billion, up 66.52%, while the annual FY2025 figure was $2.3 billion, 66.52% up from the prior year.
  • Current Assets reached $2.3 billion in Q4 2025 per PTCT's latest filing, up from $2.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $2.3 billion in Q1 2025 and bottomed at $517.3 million in Q3 2022.
  • Average Current Assets over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2021.
  • Peak YoY movement for Current Assets: tumbled 48.84% in 2022, then skyrocketed 137.17% in 2024.
  • A 5-year view of Current Assets shows it stood at $954.4 million in 2021, then decreased by 27.3% to $693.8 million in 2022, then skyrocketed by 75.65% to $1.2 billion in 2023, then rose by 12.05% to $1.4 billion in 2024, then surged by 66.52% to $2.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $2.3 billion in Q4 2025, $2.0 billion in Q3 2025, and $2.3 billion in Q2 2025.